Characterization and Biological Evaluation of Lipid Nanoparticles Delivering PPRHs Targeting HPV-16 and HPV-18 E7

Roger Fàbrega Alsina – Research Scientist, IBEC/Reig Jofre; Xavier Julià Camprodon – Head of Pharmaceutical Innovation, Reig Jofre; Jessica Malavia Muñoz – Analytical Development Technician, Reig Jofre; Anna Lagunas Targarona – Research leader, IBEC; Máté Lengyel – Research scientist, BioTalentum; Vivien Tamás – Postdoctoral research scientist, BioTalentum; Anna Meller – Senior scientist, BioTalentum; Kornél Kistamás – Cardiac specialist, BioTalentum; András Dinnyés – General Director, BioTalentum; Josep Samitier i Martí – Director of the Institute for Bioengineering of Catalonia (IBEC), IBEC; Carlos J Ciudad – Full Professor, Universidad de Barcelona; Laia Montell Bonaventura – Science Liaison, Reig Jofre; Véronique Noé - Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of
Barcelona, Spain, Institute of Nanoscience and Nanotechnology, Universitat de Barcelona (IN2UB), 08028 Barcelona,
Spain

Introduction:

High-risk human papillomaviruses HPV-16 and HPV-18 drive cervical cancer progression mainly through the viral oncoprotein E7, which disrupts cell-cycle control and promotes proliferation. DNA Polypurine Reverse Hoogsteen (PPRHs) therapeutic oligonucleotides represent a promising strategy for gene silencing including oncogenic targets, but their therapeutic potential depends on efficient intracellular delivery. This study aims to develop and evaluate lipid nanoparticles (LNPs)  encapsulating anti-E7 PPRHs against HPV-16 and HPV-18 and to assess their biological activity and safety in cervical cancer cell models.